diyhrt/transfemscience.org/articles-by-author/aly/index.html
2026-02-07 02:11:00 +00:00

1 line
No EOL
20 KiB
HTML
Raw Blame History

This file contains invisible Unicode characters

This file contains invisible Unicode characters that are indistinguishable to humans but may be processed differently by a computer. If you think that this is intentional, you can safely ignore this warning. Use the Escape button to reveal them.

<!doctype html><html lang="en-US" data-no-contents-sidebar><head><meta charset="UTF-8"><meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1"><title>Articles by Aly - Transfeminine Science</title><link rel="preload" href="../../assets/images/branding/logo.png" as="image" /><link rel="preload" href="../../assets/images/branding/logo-dark.png" as="image" /><link rel="stylesheet" href="../../assets/css/vendor/normalize.css"><link rel="stylesheet" href="../../assets/css/variables.css"><link rel="stylesheet" href="../../assets/css/site-layout.css"><link rel="stylesheet" href="../../assets/css/article-content.css"><link rel="stylesheet" href="../../assets/css/print.css"><link rel="stylesheet" href="../../assets/css/hover-refs.css"><meta name="robots" content="noarchive"><link rel="apple-touch-icon" sizes="180x180" href="../../apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="../../favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="../../favicon-16x16.png"><link rel="icon" href="../../favicon.ico"><link rel="manifest" href="../../site.webmanifest"><meta name="msapplication-TileColor" content="#ece5ff"><meta name="theme-color" content="#ffffff"><link type="application/atom+xml" rel="alternate" href="../../feed-posts.xml" title="Transfeminine Science" /><link rel="alternate" type="application/atom+xml" title="Articles by Aly - Transfeminine Science" href="../../feed.xml"><link rel="canonical" href="index.html" /><meta property="og:title" content="Articles by Aly" /><meta property="og:image" content="https://transfemscience.org/assets/images/branding/logo-alt.png" /><meta name="twitter:image" content="https://transfemscience.org/assets/images/branding/logo-alt.png" /><meta property="og:url" content="https://transfemscience.org/articles-by-author/aly/" /><meta property="og:locale" content="en_US" /><meta property="og:site_name" content="Transfeminine Science" /><meta property="og:type" content="article" /><meta name="twitter:card" content="summary" /><meta name="publisher" content="Transfeminine Science"><meta name="description" content="Articles by Aly - Transfeminine Science" /><meta property="og:description" content="Articles by Aly - Transfeminine Science" /> <script type="application/ld+json"> { "@context": "https://schema.org", "name": "Articles by Aly", "mainEntityOfPage": "https://transfemscience.org/articles-by-author/aly/", "headline": "Articles by Aly", "url": "https://transfemscience.org/articles-by-author/aly/", "isAccessibleForFree": "True", "description": "Articles by Aly", "@type": "WebPage", "publisher": { "@type": "Organization", "name": "Transfeminine Science", "url": "https://transfemscience.org", "email": "", "logo": "https://transfemscience.org/assets/images/branding/logo.png" } } </script><script type="application/ld+json"> { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://transfemscience.org/" }, { "@type": "ListItem", "position": 2, "name": "Articles by Aly" } ] } </script> <script src="../../assets/js/script.js"></script> <script src="../../assets/js/hover-refs.js" defer></script></head><body> <svg xmlns="http://www.w3.org/2000/svg" style="display: none;"> <symbol id="svg-link" viewBox="0 0 24 24"><title>Link</title><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="feather feather-link"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path> </svg> </symbol> </svg><div id="header"><div id="header-subcontainer"> <a href="../../index.html" id="site-icon-and-title-container"> <span id="site-icon">&nbsp;</span> <span id="site-title" translate="no" class="notranslate"> <span id="site-title-text-xs">TFS</span> <span id="site-title-text-sm">TFSci</span> <span id="site-title-text-md">Transfem Sci</span> <span id="site-title-text-lg">Transfeminine Science</span> </span> </a> <span id="top-links"> <a href="../../articles/index.html" class="top-link">Articles</a> <a href="../../articles-by-date/index.html" class="top-link">Latest</a> <a href="../../misc/index.html" class="top-link">Misc</a> <a href="../../about/index.html" class="top-link">About</a> </span> <span id="top-buttons"> <button id="theme-button" class="top-button" title="Theme (light/dark)"> <svg id="theme-button-light-svg" class="top-button-svg" width="20" height="20" viewBox="0 0 32 32"><path d="M16 12.005a4 4 0 1 1-4 4a4.005 4.005 0 0 1 4-4m0-2a6 6 0 1 0 6 6a6 6 0 0 0-6-6z"></path><path d="M5.394 6.813l1.414-1.415l3.506 3.506L8.9 10.318z"></path><path d="M2 15.005h5v2H2z"></path><path d="M5.394 25.197L8.9 21.691l1.414 1.415l-3.506 3.505z"></path><path d="M15 25.005h2v5h-2z"></path><path d="M21.687 23.106l1.414-1.415l3.506 3.506l-1.414 1.414z"></path><path d="M25 15.005h5v2h-5z"></path><path d="M21.687 8.904l3.506-3.506l1.414 1.415l-3.506 3.505z"></path><path d="M15 2.005h2v5h-2z"></path></svg> <svg id="theme-button-dark-svg" class="top-button-svg" width="20" height="20" viewBox="0 0 32 32"><path d="M13.502 5.414a15.075 15.075 0 0 0 11.594 18.194a11.113 11.113 0 0 1-7.975 3.39c-.138 0-.278.005-.418 0a11.094 11.094 0 0 1-3.2-21.584M14.98 3a1.002 1.002 0 0 0-.175.016a13.096 13.096 0 0 0 1.825 25.981c.164.006.328 0 .49 0a13.072 13.072 0 0 0 10.703-5.555a1.01 1.01 0 0 0-.783-1.565A13.08 13.08 0 0 1 15.89 4.38A1.015 1.015 0 0 0 14.98 3z"></path></svg> </button> <button id="language-button" class="top-button" title="Translate"> <svg class="top-button-svg" xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24"><path d="M12.65 15.67c.14-.36.05-.77-.23-1.05l-2.09-2.06.03-.03c1.74-1.94 2.98-4.17 3.71-6.53h1.94c.54.0.99-.45.99-.99v-.02c0-.54-.45-.99-.99-.99H10V3c0-.55-.45-1-1-1s-1 .45-1 1v1H1.99c-.54.0-.99.45-.99.99.0.55.45.99.99.99h10.18C11.5 7.92 10.44 9.75 9 11.35c-.81-.89-1.49-1.86-2.06-2.88-.16-.29-.45-.47-.78-.47-.69.0-1.13.75-.79 1.35.63 1.13 1.4 2.21 2.3 3.21L3.3 16.87c-.4.39-.4 1.03.0 1.42.39.39 1.02.39 1.42.0L9 14l2.02 2.02c.51.51 1.38.32 1.63-.35zM17.5 10c-.6.0-1.14.37-1.35.94l-3.67 9.8c-.24.61.22 1.26.87 1.26.39.0.74-.24.88-.61l.89-2.39h4.75l.9 2.39c.14.36.49.61.88.61.65.0 1.11-.65.88-1.26l-3.67-9.8c-.22-.57-.76-.94-1.36-.94zm-1.62 7 1.62-4.33L19.12 17h-3.24z"></path></svg> </button> <button id="search-button" class="top-button" title="Search"> <svg version="1.1" class="top-button-svg" width="24" height="24" viewBox="0 0 32 32" xmlns="http://www.w3.org/2000/svg" xmlns:sketch="http://www.bohemiancoding.com/sketch/ns" xmlns:xlink="http://www.w3.org/1999/xlink"><g><path d="M19.4271164,21.4271164 C18.0372495,22.4174803 16.3366522,23 14.5,23 C9.80557939,23 6,19.1944206 6,14.5 C6,9.80557939 9.80557939,6 14.5,6 C19.1944206,6 23,9.80557939 23,14.5 C23,16.3366522 22.4174803,18.0372495 21.4271164,19.4271164 L27.0119176,25.0119176 C27.5621186,25.5621186 27.5575313,26.4424687 27.0117185,26.9882815 L26.9882815,27.0117185 C26.4438648,27.5561352 25.5576204,27.5576204 25.0119176,27.0119176 L19.4271164,21.4271164 L19.4271164,21.4271164 Z M14.5,21 C18.0898511,21 21,18.0898511 21,14.5 C21,10.9101489 18.0898511,8 14.5,8 C10.9101489,8 8,10.9101489 8,14.5 C8,18.0898511 10.9101489,21 14.5,21 L14.5,21 Z"></path></g></svg> </button> <button id="toc-button-mobile" class="top-button" title="Article contents (Ctrl+Shift+L)"> <svg class="top-button-svg" xmlns="http://www.w3.org/2000/svg" version="1.0" width="16" height="16" viewBox="0 0 16 16"><g transform="translate(0,16) scale(0.002536,-0.002540)"><path d="M550 6274 c-81 -17 -207 -79 -282 -139 -110 -87 -202 -230 -238 -371 -20 -76 -20 -122 -20 -2618 0 -2810 -5 -2597 65 -2741 87 -180 227 -304 420 -372 l80 -28 2551 -3 2551 -2 98 25 c253 64 441 251 506 503 19 73 19 137 19 2617 0 2478 0 2544 -19 2617 -51 198 -181 361 -361 451 -53 26 -126 54 -165 62 -103 21 -5105 21 -5205 -1z m5055 -3129 l0 -2440 -2447 -3 -2448 -2 0 2445 0 2445 2448 -2 2447 -3 0 -2440z" /><path d="M1410 4893 c0 -2 0 -158 0 -348 l-1 -346 346 0 346 0 0 346 0 346 -346 2 c-190 1 -345 1 -345 0z" /><path d="M2460 4893 c0 -2 0 -158 0 -348 l-1 -345 1221 0 1221 0 0 345 0 345 -1221 3 c-671 1 -1220 1 -1220 0z" /><path d="M1407 3493 c-1 -1 -1 -157 1 -347 l3 -346 344 0 345 0 0 340 c0 187 0 342 0 345 0 5 -689 13 -693 8z" /><path d="M2457 3493 c-1 -1 -1 -157 1 -347 l3 -346 1219 0 1220 0 0 340 c0 187 -1 342 -2 345 -3 4 -2437 13 -2441 8z" /><path d="M1409 2096 c-2 -2 -3 -160 -1 -350 l3 -346 344 0 344 0 3 346 c2 190 1 348 -1 350 -6 5 -686 5 -692 0z" /><path d="M2459 2096 c-2 -2 -3 -160 -1 -350 l3 -346 1219 0 1219 0 3 346 c2 190 1 348 -1 350 -6 5 -2436 5 -2442 0z" /></g></svg> </button> <button id="menu-button-mobile-menu" class="top-button" title="Menu"> <svg class="top-button-svg" xmlns="http://www.w3.org/2000/svg" width="21" height="21" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"><path d="M 3,12 L 21,12" /><path d="M 3,6 L 21,6" /><path d="M 3,18 L 21,18" /></svg> </button> <button id="hide-persistent-header-button" class="top-button" title="Hide top bar (Ctrl+Shift+H)"> <svg id="hide-persistent-header-button-svg" version="1.1" x="0px" y="0px" width="20px" height="20px" viewBox="0 0 24 24" enable-background="new 0 0 24 24" xml:space="preserve" fill="#5F6368"><path d="M8.59,16.59L13.17,12L8.59,7.41L10,6l6,6l-6,6L8.59,16.59z"></path><path fill="none" d="M0,0h24v24H0V0z"></path></svg> </button> </span></div><div id="mobile-menu"> <span id="top-links-mobile"> <a href="../../articles/index.html" class="top-link">Articles</a> <a href="../../articles-by-date/index.html" class="top-link">Latest</a> <a href="../../misc/index.html" class="top-link">Misc</a> <a href="../../about/index.html" class="top-link">About</a> </span></div></div><button id="restore-persistent-header-button" class="top-button" title="Show top bar (Ctrl+Shift+H)"> <svg id="restore-persistent-header-button-svg" version="1.1" x="0px" y="0px" width="20px" height="20px" viewBox="0 0 24 24" enable-background="new 0 0 24 24" xml:space="preserve" fill="#5F6368"><path d="M8.59,16.59L13.17,12L8.59,7.41L10,6l6,6l-6,6L8.59,16.59z"></path><path fill="none" d="M0,0h24v24H0V0z"></path></svg> </button> <button id="sidebar-button-standalone" class="sidebar-button" title="Article contents (Ctrl+Shift+L)"> <span id="sidebar-button-standalone-icon" class="sidebar-button-icon"> <svg id="sidebar-button-standalone-icon-svg" class="sidebar-button-icon-svg" xmlns="http://www.w3.org/2000/svg" version="1.0" width="16" height="16" viewBox="0 0 16 16"><g transform="translate(0,16) scale(0.002536,-0.002540)"><path d="M550 6274 c-81 -17 -207 -79 -282 -139 -110 -87 -202 -230 -238 -371 -20 -76 -20 -122 -20 -2618 0 -2810 -5 -2597 65 -2741 87 -180 227 -304 420 -372 l80 -28 2551 -3 2551 -2 98 25 c253 64 441 251 506 503 19 73 19 137 19 2617 0 2478 0 2544 -19 2617 -51 198 -181 361 -361 451 -53 26 -126 54 -165 62 -103 21 -5105 21 -5205 -1z m5055 -3129 l0 -2440 -2447 -3 -2448 -2 0 2445 0 2445 2448 -2 2447 -3 0 -2440z" /><path d="M1410 4893 c0 -2 0 -158 0 -348 l-1 -346 346 0 346 0 0 346 0 346 -346 2 c-190 1 -345 1 -345 0z" /><path d="M2460 4893 c0 -2 0 -158 0 -348 l-1 -345 1221 0 1221 0 0 345 0 345 -1221 3 c-671 1 -1220 1 -1220 0z" /><path d="M1407 3493 c-1 -1 -1 -157 1 -347 l3 -346 344 0 345 0 0 340 c0 187 0 342 0 345 0 5 -689 13 -693 8z" /><path d="M2457 3493 c-1 -1 -1 -157 1 -347 l3 -346 1219 0 1220 0 0 340 c0 187 -1 342 -2 345 -3 4 -2437 13 -2441 8z" /><path d="M1409 2096 c-2 -2 -3 -160 -1 -350 l3 -346 344 0 344 0 3 346 c2 190 1 348 -1 350 -6 5 -686 5 -692 0z" /><path d="M2459 2096 c-2 -2 -3 -160 -1 -350 l3 -346 1219 0 1219 0 3 346 c2 190 1 348 -1 350 -6 5 -2436 5 -2442 0z" /></g></svg> </span> </button><div id="mid-section"><div id="sidebar"><div id="sidebar-subcontainer"><div id="sidebar-title-container"> <button id="sidebar-button" class="sidebar-button" title="Article contents (Ctrl+Shift+L)"> <span class="sidebar-button-icon"> <svg class="sidebar-button-icon-svg" xmlns="http://www.w3.org/2000/svg" version="1.0" width="16" height="16" viewBox="0 0 16 16"><g transform="translate(0,16) scale(0.002536,-0.002540)"><path d="M550 6274 c-81 -17 -207 -79 -282 -139 -110 -87 -202 -230 -238 -371 -20 -76 -20 -122 -20 -2618 0 -2810 -5 -2597 65 -2741 87 -180 227 -304 420 -372 l80 -28 2551 -3 2551 -2 98 25 c253 64 441 251 506 503 19 73 19 137 19 2617 0 2478 0 2544 -19 2617 -51 198 -181 361 -361 451 -53 26 -126 54 -165 62 -103 21 -5105 21 -5205 -1z m5055 -3129 l0 -2440 -2447 -3 -2448 -2 0 2445 0 2445 2448 -2 2447 -3 0 -2440z" /><path d="M1410 4893 c0 -2 0 -158 0 -348 l-1 -346 346 0 346 0 0 346 0 346 -346 2 c-190 1 -345 1 -345 0z" /><path d="M2460 4893 c0 -2 0 -158 0 -348 l-1 -345 1221 0 1221 0 0 345 0 345 -1221 3 c-671 1 -1220 1 -1220 0z" /><path d="M1407 3493 c-1 -1 -1 -157 1 -347 l3 -346 344 0 345 0 0 340 c0 187 0 342 0 345 0 5 -689 13 -693 8z" /><path d="M2457 3493 c-1 -1 -1 -157 1 -347 l3 -346 1219 0 1220 0 0 340 c0 187 -1 342 -2 345 -3 4 -2437 13 -2441 8z" /><path d="M1409 2096 c-2 -2 -3 -160 -1 -350 l3 -346 344 0 344 0 3 346 c2 190 1 348 -1 350 -6 5 -686 5 -692 0z" /><path d="M2459 2096 c-2 -2 -3 -160 -1 -350 l3 -346 1219 0 1219 0 3 346 c2 190 1 348 -1 350 -6 5 -2436 5 -2442 0z" /></g></svg> </span> </button> <span id="sidebar-title">Contents</span></div><div id="sidebar-contents"><div class="toc-h1"><a id="heading-0" href="index.html#top" class="toc-link">Top of page</a></div></div></div></div><div id="main-area"><div id="article"><h1 id="articles-by-aly-latest-first"> <a href="index.html#articles-by-aly-latest-first" aria-labelledby="articles-by-aly-latest-first" class="anchor-heading"><svg viewBox="0 0 16 16" aria-hidden="true"><use xlink:href="#svg-link"></use></svg></a> Articles by <a href="../../about/index.html#aly">Aly</a> (Latest First)</h1><p>   Filter by author: <strong>Aly</strong> | <a href="../sam/index.html">Sam</a> | <a href="../lain/index.html">Lain</a> | <a href="../mitzi/index.html">Mitzi</a> | <a href="../../articles-by-date/index.html">All</a></p><ul><li><p><a href="../../articles/injectable-e2-simulator-release/index.html">An Interactive Web Simulator for Estradiol Levels with Injectable Estradiol Esters</a> (Aly, July 2021)</p></li><li><p><a href="../../articles/injectable-e2-meta-analysis/index.html">An Informal Meta-Analysis of Estradiol Curves with Injectable Estradiol Preparations</a> (Aly, July 2021)</p></li><li><p><a href="../../articles/transfem-hormone-guidelines/index.html">Clinical Guidelines with Information on Transfeminine Hormone Therapy</a> (Aly, November 2020)</p></li><li><p><a href="../../articles/spiro-visceral-fat/index.html">Spironolactone and Claims About Increased Visceral Fat in Transfeminine People</a> (Aly, October 2020)</p></li><li><p><a href="../../articles/estrogens-blood-clots/index.html">Estrogens and Their Influences on Coagulation and Risk of Blood Clots</a> (Aly, October 2020)</p></li><li><p><a href="../../articles/shbg-unimportant/index.html">The Interactions of Sex Hormones with Sex Hormone-Binding Globulin and Relevance for Transfeminine Hormone Therapy</a> (Aly, July 2020)</p></li><li><p><a href="../../articles/shbg-unimportant-suppl/index.html">Supplement: The Interactions of Sex Hormones with Sex Hormone-Binding Globulin and Relevance for Transfeminine Hormone Therapy</a> (Aly, July 2020)</p></li><li><p><a href="../../articles/bica-adoption/index.html">Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy</a> (Aly, July 2020)</p></li><li><p><a href="../../articles/hormone-levels-female-puberty/index.html">Hormone Levels During Normal Puberty in Cisgender Girls</a> (Aly, April 2020)</p></li><li><p><a href="../../articles/breast-cancer/index.html">Breast Cancer Risk with Hormone Therapy in Transfeminine People</a> (Aly, April 2020)</p></li><li><p><a href="../../articles/breast-cancer-suppl/index.html">The Possible Role of a Second X Chromosome in Breast Cancer Risk</a> (Aly, April 2020)</p></li><li><p><a href="../../articles/cpa-meningioma/index.html">Recent Developments on Cyproterone Acetate and Meningioma Risk Out of France and Implications for Transfeminine People</a> (Aly, April 2020)</p></li><li><p><a href="../../articles/e2-equivalent-doses/index.html">Approximate Comparable Dosages of Estradiol by Different Routes</a> (Aly, April 2020)</p></li><li><p><a href="../../articles/nandrolone/index.html">Nandrolone as a Potential Alternative Androgen with Reduced Androgenic Side Effects for Transfeminine and Transmasculine People</a> (Aly, March 2020)</p></li><li><p><a href="../../articles/progestogens-breast-dev/index.html">A Comprehensive Review of the Potential of Progestogens for Enhancing Breast Development in Transfeminine People</a> (Aly, February 2020)</p></li><li><p><a href="../../articles/progestogens-sexual-desire/index.html">The Influence of Progesterone and Other Progestogens on Sexual Desire and Function</a> (Aly, January 2020)</p></li><li><p><a href="../../articles/progestogens-early-exposure-breast-dev/index.html">Literature on Early Progestogen Exposure and Breast Development</a> (Aly, July 2019)</p></li><li><p><a href="../../articles/cpa-dosage/index.html">Low Doses of Cyproterone Acetate Are Maximally Effective for Testosterone Suppression in Transfeminine People</a> (Aly, July 2019)</p></li><li><p><a href="../../articles/high-dose-transdermal-e2/index.html">A Review of Studies on Estradiol Levels and Testosterone Suppression with High-Dose Transdermal Estradiol Gel and Ointment in Cisgender Men with Prostate Cancer</a> (Aly, June 2019)</p></li><li><p><a href="../../articles/aqueous-suspensions/index.html">Injectable Aqueous Suspensions of Sex Hormones and How Depot Injectables Work</a> (Aly, June 2019)</p></li><li><p><a href="../../articles/nonbinary-transfem-overview/index.html">An Exploration of Possibilities for Hormone Therapy in Non-Binary Transfeminine People</a> (Aly, June 2019)</p></li><li><p><a href="../../articles/genital-e2-application/index.html">Genital Application via the Scrotum and Neolabia for Greatly Enhanced Absorption of Transdermal Estradiol in Transfeminine People</a> (Aly, March 2019)</p></li><li><p><a href="../../articles/oral-e2-leinung-2018/index.html">Analysis of Estradiol and Testosterone Levels with Oral Estradiol in Transfeminine People Based on Leinung et al. (2018)</a> (Aly, March 2019)</p></li><li><p><a href="../../articles/transfem-lactation-literature/index.html">Published Case Reports of Lactation and/or Breastfeeding in Transfeminine People</a> (Aly, March 2019)</p></li><li><p><a href="../../articles/sublingual-ev/index.html">Sublingual Administration of Oral Estradiol Valerate Tablets for Transfeminine People</a> (Aly, January 2019)</p></li><li><p><a href="../../articles/spiro-testosterone/index.html">A Review of Studies on Spironolactone and Testosterone Suppression in Cisgender Men, Cisgender Women, and Transfeminine People</a> (Aly, December 2018)</p></li><li><p><a href="../../articles/buserelin-inexpensive/index.html">Buserelin, a Gonadotropin-Releasing Hormone Agonist, is Inexpensively Available as a Nasal Spray From Online Pharmacies</a> (Aly, August 2018)</p></li><li><p><a href="../../articles/oral-p4-low-levels/index.html">Oral Progesterone Achieves Very Low Levels of Progesterone and Has Only Weak Progestogenic Effects</a> (Aly, August 2018)</p></li><li><p><a href="../../articles/oral-p4-low-levels-literature/index.html">Sources/Excerpts: Oral Progesterone Achieves Very Low Levels of Progesterone and Has Only Weak Progestogenic Effects</a> (Aly, August 2018)</p></li><li><p><a href="../../articles/transfem-intro/index.html">An Introduction to Hormone Therapy for Transfeminine People</a> (Aly, August 2018)</p></li><li><p><a href="../../articles/ec508/index.html">EC508 (Estradiol Aminosulfonylbenzoylproline), a Unique and Highly Promising Estradiol Ester and Possible Oral Estradiol Form of the Future</a> (Aly, August 2018)</p></li></ul></div></div><div id="footer"> <span id="footer-subcontainer"> <span id="site-copyright">&copy; 2026 <span translate="no" class="notranslate">Transfeminine Science</span></span> </span></div></div></body></html>